This abridged Novartis case by Dr. Kalyan C. Kankanala explains the patentability requirements under Section 3(d) of Indian patent law. It provides a structured analysis of the legal and practical issues surrounding the Imatinib Mesylate patent application.
Read more about Patentability and Section 3(d), History of Patent Law in India, Patentability of Imatinib Masylate in Beta Crystalline Form – Novartis Case Abridged by Dr. Kalyan C. KankanalaTag: Novartis Case
The 3D Effect of Novartis Case on Genetic Inventions
The Novartis case established a strict test for therapeutic efficacy under Section 3(d) of the Indian Patents Act, influencing the patentability of genetic inventions. This post examines the impact on gene sequence patents and the ongoing legal debate regarding their compliance with Indian patent law.
Read more about The 3D Effect of Novartis Case on Genetic Inventions